Cargando…

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis

Vertebral fractures (VFx) are the most common type of fracture in postmenopausal osteoporosis (PMO). VFx are generally classified using the Genant grading system as mild (grade 1), moderate (grade 2), or severe (grade 3) according to their degree of compression visualized on spinal x-rays. Regardles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feldman, Robert, Geusens, Piet, Oates, Mary, Thomas, Thierry, Makras, Polyzois, Jakob, Franz, Langdahl, Bente, Yang, Wenjing, Rojeski, Maria, Libanati, Cesar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Bone and Mineral Metabolism
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207838/ http://dx.doi.org/10.1210/jendso/bvaa046.048

Ejemplares similares

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

SAT232 Patients With Chronic Hypoparathyroidism Have Higher Risk Of Vertebral Fracture And Lower Risk Of Femoral Fracture Compared To Controls
por: Bjornsdottir, Sigridur, et al.
Publicado: (2023)

Radiotherapy-Associated Pelvic Insufficiency Fracture Treated by Romosozumab: Course of L1 and L5 Vertebral Body CT Attenuation
por: Adly, Hussein, et al.
Publicado: (2021)

RF30 | PSAT138 Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient with Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

ODP132 Efficacy of Romosozumab for Osteoporosis in a Patient with Hajdu-Cheney Syndrome: A Case Report
por: Kim, Kyoung Jin, et al.
Publicado: (2022)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
por: Saag, Kenneth, et al.
Publicado: (2019)

FRI683 Every Dose Counts: Response To Half The Recommended Dose Of Romosozumab
por: Ramchandani, Bhanvi Prakash, et al.
Publicado: (2023)

T‐Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

THU433 Spontaneous Vertebral Fractures In The Setting Of Prolonged CRRT
por: Akanbi, Folake, et al.
Publicado: (2023)

OR13-03 Understanding Why Older People with Low Trauma Fractures Die Prematurely
por: Tran, Thach, et al.
Publicado: (2020)

MON-377 Fracture Site in High-Energy Trauma Is Associated with Osteoporosis Risk
por: Chourpiliadis, Charilaos Paulos, et al.
Publicado: (2020)

Ethnicity, Ethnic Language, and Fracture Risk Conditions in Women Initiating Osteoporosis Therapy
por: Lo, Joan Chia-Mei, et al.
Publicado: (2021)

ODP090 Fragility Fractures and Osteoporosis Screening in Patients with Chronic Lymphocytic Leukemia
por: Petty, Lloyd, et al.
Publicado: (2022)

SUN-378 Unilateral Primary Aldosteronism as an Independent Risk Factor for Vertebral Fracture
por: Sakamoto, Ryuichi, et al.
Publicado: (2020)

THU448 Multiple Non-traumatic Vertebral Fractures After Discontinuation Of Denosumab
por: Riahi, Shayan, et al.
Publicado: (2023)

THU423 Recognizing Secondary Contributors Of Osteoporosis In A Hip Fracture Cohort In Singapore
por: Tay, Wei Lin, et al.
Publicado: (2023)

SAT-389 Clinical and Biochemical Characterization of Risk Factors for Vertebral Fractures in Patients with Hypoparathyroidism
por: Formenti, Anna Maria, et al.
Publicado: (2020)

Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab
por: Caseja, Ahl Jeffrey, et al.
Publicado: (2021)

MON-LB71 Adult Hypophosphatasia and Postmenopausal Osteoporosis: A Challenging Case
por: Abramof-Ness, Rosane, et al.
Publicado: (2020)

Bilateral Sacral Stress Fracture in Pregnancy without Osteoporosis - A Case Report and Literature Review
por: Wu, Yu-Fang, et al.
Publicado: (2021)

SUN-370 Validation of a Deep Learning Based Algorithm to Diagnose Vertebral Compression Fractures
por: Page, John, et al.
Publicado: (2020)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

THU411 Fracture And Osteoporosis In Hereditary Connective Tissue Disorders: A Systematic Review And Meta-analysis
por: Charoenngam, Nipith, et al.
Publicado: (2023)

OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss
por: Sølling, Anne Sophie K, et al.
Publicado: (2020)

RF18 | PSAT165 Effect of Age, Gender, & Ethnicity on the Prevalence of Vertebral fractures in Patients with Primary Hyperparathyroidism
por: Al-Bacha, Souad, et al.
Publicado: (2022)

Progress in osteoporosis and fracture prevention: focus on postmenopausal women
por: Saag, Kenneth G, et al.
Publicado: (2009)

SUN-386 Treatment Outcomes of Intravenous Zoledronic Acid vs Oral Alendronate in Postmenopausal Women with Osteoporosis
por: Pyone, Zar Chi, et al.
Publicado: (2020)

SUN-389 Trends in Osteoporosis Treatment Uptake and Persistence Among Postmenopausal Women in the U.S., 2010–2015
por: Kim, Min, et al.
Publicado: (2020)

OR13-02 Ethnic Variation In Non-vertebral Major Osteoporotic Fractures Among US Asian/Pacific Islander Men
por: Chu, Clarence E, et al.
Publicado: (2023)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Clinical Risk Factors for Osteoporotic Fractures in Men With Non-Metastatic Prostate Cancer on Androgen Deprivation Therapy With or Without Anti-Osteoporosis Treatment
por: Sonnabend, Hajerah, et al.
Publicado: (2021)

THU429 Improvement Of Osteoporosis Evaluation And Management In Patients Admitted With Hip Fractures At A Tertiary Level Academic Healthcare Institution In Manhattan
por: Haridas, Keerthana, et al.
Publicado: (2023)

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

OR13-07 Crystal Bone: Personalized, Short-Term Fracture Risk Prediction with Natural Language Processing Methods
por: Almog, Yasmeen, et al.
Publicado: (2020)

Therapeutic Potentials of Dimeric (Cys25)PTH(1–34) Peptide for Osteoporosis and Fracture Healing of the Bones- Buy One, Get One Free
por: Park, Doori, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7mmhkjqssovr9o8hp5ug9gv0n1